NPLEx; require manufacturers of certain pseudoephedrine or ephedrine products to pay fees to support the administration of.
Summary
SB 2733 amends Mississippi’s controlled sales rules for pseudoephedrine and ephedrine products, which are common ingredients in over-the-counter cold and allergy medicines. The bill keeps the existing limits on nonprescription sales, including daily and 30-day purchase caps, age and identification requirements, behind-the-counter storage, pharmacist supervision, and the use of the National Precursor Log Exchange (NPLEx) before a sale can be completed. It also preserves the stop-sale alert system, the emergency override option for retail employees facing a reasonable fear of imminent bodily harm, and the requirement that transaction records be maintained electronically or by alternate means during system failures.
The main substantive change is that, beginning October 1, 2025, manufacturers of lawful pseudoephedrine or ephedrine products sold in or into Mississippi must pay monthly fees to the National Association of Drug Diversion Investigators to support NPLEx administration. The association would set the fee levels, and manufacturers must provide written proof of payment to the Mississippi State Board of Pharmacy upon request. The bill also retains existing exemptions for legitimate prescriptions and the rule that prescription-dispensed amounts do not count toward the nonprescription purchase limits.
Impact
The bill would amend Section 73-21-124 of the Mississippi Code, adding a new manufacturer-fee requirement tied to NPLEx while leaving the state’s pseudoephedrine/ephedrine retail controls largely intact. It would shift part of the cost of operating the precursor-tracking system from pharmacies and retailers to manufacturers of covered products sold in Mississippi, and it would give the Mississippi State Board of Pharmacy a new enforcement/documentation role regarding fee payment. The bill does not change the underlying criminal penalties, purchase limits, or prescription exemptions already in law.
Sentiment
Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the measure appears to be framed as a technical and enforcement-oriented update rather than a controversial policy overhaul. Its stated purpose is to support the existing NPLEx system used to monitor pseudoephedrine and ephedrine sales and to strengthen compliance oversight. No recorded opposition or support is available in the supplied history, so the overall sentiment cannot be measured from debate or roll-call data.
Contention
The most likely point of contention is the new monthly fee obligation imposed on manufacturers, since it creates a direct financial burden and gives NADI authority to set fee levels. Retail pharmacies and pharmacies may support the bill if it helps sustain NPLEx without charging them access fees, while manufacturers could object to the added cost and the lack of a statutory fee cap. A secondary issue is the continued reliance on electronic tracking and stop-sale alerts, which can raise concerns about administrative burden, privacy, and operational disruptions for pharmacies and retailers, though the bill itself does not alter those core requirements.